James Gordon
Stock Analyst at Barclays
(2.76)
# 1,788
Out of 5,116 analysts
11
Total ratings
77.78%
Success rate
19.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Gordon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GSK GSK plc | Downgrades: Underweight | n/a | $51.60 | - | 1 | Jan 6, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $925 → $1,100 | $840.50 | +30.87% | 8 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $7.6 → $10 | $9.25 | +11.35% | 1 | Jun 17, 2025 | |
| GMAB Genmab | Downgrades: Neutral | n/a | $32.63 | - | 1 | Aug 20, 2024 |
GSK plc
Jan 6, 2026
Downgrades: Underweight
Price Target: n/a
Current: $51.60
Upside: -
argenx SE
Dec 8, 2025
Maintains: Overweight
Price Target: $925 → $1,100
Current: $840.50
Upside: +30.87%
Grifols
Jun 17, 2025
Maintains: Neutral
Price Target: $7.6 → $10
Current: $9.25
Upside: +11.35%
Genmab
Aug 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $32.63
Upside: -